Chart of the Week: Alzheimer’s Biomarker and Trial Landscape

This week’s CotW includes the landscape of biomarkers and clinical trials for Alzheimer’s disease.  There is significant clustering around two biomarkers, but many interesting emerging biomarkers in clinical trials. Gray: Disease Blue: Biomarkers...

Testing Rates Seem to Be Low for Psychiatric Drug Metabolism

As previously reported, psychiatric drugs are among the most likely to be involved genetically-mediated drug toxicity, due to mutations in various metabolizing cytochrome p450 genes. We conducted an informal survey on a LinkedIn group for psychiatrists, asking them...

Should psychiatrists be testing their patients for drug response?

We have just conducted a review of the biomarkers in drug labels to complete the population of the theranostic clinical biomarkers in BiomarkerBase™, and it was not surprising to note how well-represented the cytochrome p450’s are in the labels of approved...